Yonsei Med J.  2015 Jan;56(1):307-308. 10.3349/ymj.2015.56.1.307.

Intralesional 3% Sodium Tetradecyl Sulfate for Treatment of Cutaneous Kaposi's Sarcoma

• Kim JY
• Kim JS
• Kim MH
• Park BC
• Hong SP

• KMID: 2352823
• DOI: http://doi.org/10.3349/ymj.2015.56.1.307

Abstract

No abstract available.

MeSH Terms

Aged, 80 and over
Female
Humans
Injections, Intralesional
Sarcoma, Kaposi/*drug therapy
Skin Neoplasms/*drug therapy
Sodium Tetradecyl Sulfate/*administration & dosage/*therapeutic use
Sodium Tetradecyl Sulfate

Figure

• 

  Fig. 1 The gradual improvement of Kaposi's sarcoma on the right ankle and dorsum of foot after treatment. (A) Before treatment. Regardless of the size, all nodular lesions and plaque lesions were treated with 3% STS. (B) After 6th cycle of intralesional injection of 3% STS. STS, Sodium Tetradecyl Sulfate.

Reference

1. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, De la Rosa-García E, Volkow-Fernández P, Súchil-Bernal L, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002; 38:460–467.

2. Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol. 2008; 68:242–249.

3. Célestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, Morel P, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008; 58:585–591.

4. Muzyka BC, Glick M. Sclerotherapy for the treatment of nodular intraoral Kaposi's sarcoma in patients with AIDS. N Engl J Med. 1993; 328:210–211.

5. Benomar S, Boutayeb S, Benzekri L, Errihani H, Hassam B. Kaposi's sarcoma responding to topical imiquimod 5% cream: a case report. Cases J. 2009; 2:7092.